<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7506210\results\search\testTrace\results.xml">
  <result pre="concentration of 7.43â€‰nM, 80R scFv can neutralize &amp;gt;50% of the" exact="testing" post="wells from SARS-CoV infection. In most cases, the bivalent"/>
  <result pre="protected. Meanwhile, m396 showed significant, but incomplete, protection against SZ16" exact="infection" post="in mice. By analyzing the key residues of m396"/>
  <result pre="in vitro. The NMAb 201 completely protected mice against SARS-CoV" exact="infection" post="at a concentration of 40â€‰mg/kg. In doses as low"/>
  <result pre="RBD of SARS-CoV S protein,23 suggesting that F26G18 neutralizes SARS-CoV" exact="infection" post="by blocking RBD-ACE2 the binding. Using hybridoma technology, 26"/>
  <result pre="S protein expressed on the cell surface and inhibit the" exact="infection" post="of SARS-CoV pseudovirus with an IC50 value of 0.061â€‰Î¼g/ml."/>
  <result pre="RBD of the SARS-CoV-2 S protein. In a pseudotyped virus" exact="neutralization assay," post="monomeric sdAb 3F11 showed neutralization activity with an IC50"/>
  <result pre="with an IC50 value of 0.4360â€‰Âµg/ml in a live virus" exact="neutralization assay." post="The results of a competitive ligand-binding assay suggested that"/>
  <result pre="ACE2) for binding to RBD, indicating that ab1 neutralizes SARS-CoV-2" exact="infection" post="by blocking RBD-ACE2 binding. The ab1 IgG1 could completely"/>
  <result pre="by sequence alignment results. This indicates that either natural SARS-CoV-2" exact="infection" post="or RBD-based vaccines could stimulate the quick production of"/>
  <result pre="rhesus macaque model infected with SARS-CoV-2 in both prophylactic and" exact="treatment" post="settings and showed a considerable effect. Investigating the neutralization"/>
  <result pre="results showed that B38 had higher potency to inhibit viral" exact="infection" post="with an IC50 value of 0.177â€‰Î¼g/ml. This was followed"/>
  <result pre="of 0.177â€‰Î¼g/ml. This was followed by H4, which inhibited viral" exact="infection" post="with an IC50 value of 0.896â€‰Î¼g/ml. The crystal structure"/>
  <result pre="with the RBD-ACE2 binding interface, suggesting that B38 neutralizes SARS-CoV-2" exact="infection" post="by functionally mimicking ACE2 to bind RBD and block"/>
  <result pre="RBD. 7B11 showed cross-neutralization activity against SARS-CoV-2 in a pseudovirus" exact="neutralization assay," post="neutralizing about 80% of pseudovirus at 10â€‰Î¼g/ml. According to"/>
  <result pre="rRBD-16 had no blocking or neutralizing activity. In a pseudovirus" exact="neutralization assay," post="rRBD-15 showed potent neutralization activity against SARS-CoV-2 pseudovirus infection"/>
  <result pre="neutralization assay, rRBD-15 showed potent neutralization activity against SARS-CoV-2 pseudovirus" exact="infection" post="with an IC50 of 12.2 nM.37 VHH-72 has been"/>
  <result pre="out the memory B cells of positive plasma samples. Using" exact="reverse transcription polymerase chain reaction," post="they next cloned the VH and VL of IgG"/>
  <result pre="memory B cells of positive plasma samples. Using reverse transcription" exact="polymerase chain reaction," post="they next cloned the VH and VL of IgG"/>
  <result pre="from convalescent patients and specific mAbs were obtained using high-throughput" exact="screening" post="with specific antigen. A neutralization assay for the pseudovirus"/>
  <result pre="mAbs were obtained using high-throughput screening with specific antigen. A" exact="neutralization assay" post="for the pseudovirus of SARS-CoV-2 and a protection assay"/>
  <result pre="an IC50 value of 8â€‰ng/ml and potently inhibited live SARS-CoV-2" exact="infection" post="with IC50 values of 7 and 9â€‰ng/ml, respectively. To"/>
  <result pre="H11 that specifically binds to SARS-CoV-2 RBD was identified by" exact="screening" post="a naive llama phage display antibody library. Through random"/>
  <result pre="161â€‰nM for H11-D4-Fc, respectively. The results from the plaque reduction" exact="neutralization assay" post="showed that H11-H4-Fc and H11-D4-Fc could neutralize live SARS-CoV-2"/>
  <result pre="assay showed that H11-H4-Fc and H11-D4-Fc could neutralize live SARS-CoV-2" exact="infection" post="with the ND50 of 6â€‰nM and 18â€‰nM, respectively. Combining"/>
  <result pre="levels. H014 IgG could effectively neutralize SARS-CoV-2 and SARS-CoV pseudovirus" exact="infection" post="with IC50 of 3 and 1â€‰nM respectively, and can"/>
  <result pre="convalescent patients in Wuhan, some NMAbs were identified from the" exact="screening" post="with SARS-CoV-2 S protein.46 The IC50 of these NMAbs"/>
  <result pre="in a range of 15â€&quot;4000â€‰ng/ml as measured with focus reduction" exact="neutralization test." post="Among of them, COV2-2196 and COV2-2130 could also neutralize"/>
  <result pre="most potent NMAb 2â€&quot;15 could neutralize pseudotyped and live SARS-CoV-2" exact="infection" post="with IC50 of 5â€‰ng/ml and 0.7â€‰ng/ml, respectively, by binding"/>
  <result pre="S protein expressed on the cell surface and inhibit the" exact="infection" post="of SARS-CoV-2 pseudovirus with an IC50 value of 0.061â€‰Î¼g/ml."/>
  <result pre="RBD. 18F3 showed cross-neutralization activity against SARS-CoV-2 in the pseudovirus" exact="neutralization assay," post="neutralizing about 80% of pseudovirus at 10â€‰Î¼g/ml. However, 18F3"/>
  <result pre="we need to develop prophylactic and therapeutic drugs against coronavirus" exact="infection" post="as soon as possible. Antibody drugs with the characteristics"/>
  <result pre="effects and significant curative effect are good choices for the" exact="treatment" post="of coronavirus infection, and the RBD is the most"/>
  <result pre="Indeed, therapeutic antibody cocktails have been used successfully for the" exact="treatment" post="of patients infected with Ebola virus.57 Among NMAbs we"/>
  <result pre="to obtain human antibodies include (i) humanizing mouse mAbs,61 (ii)" exact="screening" post="for mAbs from phage display libraries of human antibody"/>
  <result pre="followed by hybridoma technology for production of mAbs.63 In addition," exact="screening" post="of antibodies from patients is the most straightforward and"/>
  <result pre="16.ter MeulenJet al.Human monoclonal antibody as prophylaxis for SARS coronavirus" exact="infection" post="in ferretsLancet20043632139214115220038 17.ChouTHet al.Epitope mapping and biological function analysis"/>
  <result pre="SARS-CoV-2 and SARS-CoV by a potent therapeutic antibodyScience20203691505150932703908 46.ZostSJet al.Rapid" exact="isolation" post="and profiling of a diverse panel of human monoclonal"/>
 </snippets>
</snippetsTree>
